---
title: Cancer screening and early detection
videoId: Dyid7vWO0zI
---

From: [[foundmyfitness]] <br/> 

Cancer screening and early detection are crucial components of a comprehensive health strategy, especially given the current limitations in understanding and preventing many types of cancer <a class="yt-timestamp" data-t="02:12:48">[02:12:48]</a>. Unlike [[effects_of_exercise_on_cardiovascular_health_and_cancer_prevention | cardiovascular disease]], which is mechanistically well-understood, cancer remains a significant "black box" <a class="yt-timestamp" data-t="02:12:51">[02:12:51]</a>. Many individuals who practice optimal [[lifestyle_changes_for_cancer_risk_reduction | lifestyle changes for cancer risk reduction]] still develop cancer <a class="yt-timestamp" data-t="02:13:01">[02:13:01]</a>.

> [!info] Cancer vs. Cardiovascular Disease
> Cancer is the leading cause of death globally and in the U.S. for both men and women <a class="yt-timestamp" data-t="02:32:38">[02:32:38]</a>.
>
> While [[effects_of_exercise_on_cardiovascular_health_and_cancer_prevention | cardiovascular disease]] is the number one killer, our mechanistic understanding and tools for prevention are superior compared to cancer and neurodegenerative diseases <a class="yt-timestamp" data-t="03:09:56">[03:09:56]</a>. Globally, the gap between cardiovascular disease and cancer deaths is significant: approximately 19 million people annually die from cardiovascular disease compared to 12-13 million from cancer <a class="yt-timestamp" data-t="03:00:23">[03:00:23]</a>.

The biggest non-modifiable risk factor for cancer is age <a class="yt-timestamp" data-t="02:08:38">[02:08:38]</a>. The leading modifiable risk factor is smoking, followed by [[obesity_and_its_connection_to_diseases_like_cancer | obesity]] <a class="yt-timestamp" data-t="02:09:12">[02:09:12]</a>, which is linked to increased growth factors (like hyperinsulinemia and IGF) and an inflammatory environment <a class="yt-timestamp" data-t="02:09:42">[02:09:42]</a>. Fat accumulation around organs (visceral fat) is particularly harmful, contributing to insulin resistance and inflammation <a class="yt-timestamp" data-t="02:10:04">[02:10:04]</a>.

## Why Aggressive Screening?

Aggressive screening is essential because earlier detection of cancer consistently leads to better outcomes <a class="yt-timestamp" data-t="02:14:25">[02:14:25]</a>.

> [!example] The Impact of Early Detection
> For Stage 3 colon cancer, which has spread to lymph nodes but not visibly beyond, the 5-year survival rate with standard chemotherapy (FOLF OX regimen) is 65% <a class="yt-timestamp" data-t="02:15:30">[02:15:30]</a>.
>
> In contrast, for Stage 4 colon cancer (with visible metastatic disease, e.g., in the liver) at the time of surgery, none of those patients will be alive in 5 years, even with the same chemotherapy <a class="yt-timestamp" data-t="02:15:52">[02:15:52]</a>. This stark difference applies to all cancers: the more cancer cells present, the greater the heterogeneity of mutations, making treatment and immune evasion more challenging <a class="yt-timestamp" data-t="02:16:04">[02:16:04]</a>.

While living a metabolically healthy life and avoiding smoking are crucial, they account for less than half of cancer cases <a class="yt-timestamp" data-t="02:13:40">[02:13:40]</a>. Therefore, aggressive screening becomes the "missing link" to bridge this gap <a class="yt-timestamp" data-t="02:14:10">[02:14:10]</a>. Moreover, early screening is significantly cheaper than treating late-stage cancer with expensive drugs <a class="yt-timestamp" data-t="02:16:41">[02:16:41]</a>.

## Understanding Screening Tests

Before undergoing aggressive screening, individuals must understand their risk appetite and the "price" of screening <a class="yt-timestamp" data-t="02:18:21">[02:18:21]</a>. This includes economic costs (many aggressive screenings are not covered by standard insurance) <a class="yt-timestamp" data-t="02:18:31">[02:18:31]</a> and the emotional cost of false positives <a class="yt-timestamp" data-t="02:19:27">[02:19:27]</a>.

Key statistical terms to understand for screening tests:
*   **Sensitivity:** The ability of a test to detect a condition when it is present <a class="yt-timestamp" data-t="02:20:14">[02:20:14]</a>.
*   **Specificity:** The ability of a test to conclude that something is absent when it is indeed absent <a class="yt-timestamp" data-t="02:20:23">[02:20:23]</a>.
*   **Prevalence/Pre-test Probability:** How likely an individual is to have the condition before testing <a class="yt-timestamp" data-t="02:20:32">[02:20:32]</a>.
*   **Positive Predictive Value (PPV):** If the test is positive, how likely is the person to actually have the condition <a class="yt-timestamp" data-t="02:19:50">[02:19:50]</a>.
*   **Negative Predictive Value (NPV):** If the test is negative, how likely is the person to truly not have the condition <a class="yt-timestamp" data-t="02:20:00">[02:20:00]</a>.

No single test is perfect; combining different modalities often increases positive and negative predictive values <a class="yt-timestamp" data-t="02:31:31">[02:31:31]</a>.

## Specific Screening Methods

### Breast Cancer Screening
*   **Mammography:** Has a sensitivity of about 90% and specificity of 85% <a class="yt-timestamp" data-t="02:21:00">[02:21:00]</a>. It is good at detecting calcified lesions but poor at non-calcified ones <a class="yt-timestamp" data-t="02:22:12">[02:22:12]</a>. For younger, pre-menopausal women, dense glandular tissue makes mammograms less effective <a class="yt-timestamp" data-t="02:21:52">[02:21:52]</a>. The radiation exposure from mammograms is very low <a class="yt-timestamp" data-t="02:33:39">[02:33:39]</a>.
*   **MRI:** Excellent for dense glandular tissue and non-calcified lesions, but poor at calcified lesions <a class="yt-timestamp" data-t="02:22:19">[02:22:19]</a>. MRI uses no radiation <a class="yt-timestamp" data-t="02:35:40">[02:35:40]</a>.
*   **Ultrasound:** Often combined with mammography for better accuracy.

> [!recommendation] Screening Strategy for Breast Cancer
> For a woman at age 40 with a lifetime risk of one in eight for breast cancer, a recommended strategy is to perform a mammogram and an ultrasound every year, staggered by six months, if risk is high enough <a class="yt-timestamp" data-t="02:25:02">[02:25:02]</a>. Catching breast cancer in Stage 1 makes it a non-fatal disease, whereas Stage 4 is uniformly fatal <a class="yt-timestamp" data-t="02:25:38">[02:25:38]</a>.

### Colon Cancer Screening
*   **Colonoscopy:** Considered a highly sensitive (100%) and specific test <a class="yt-timestamp" data-t="02:22:44">[02:22:44]</a>. It allows direct visual inspection and polyp removal, which prevents cancer formation since colon cancer almost always originates from polyps <a class="yt-timestamp" data-t="02:23:53">[02:23:53]</a>.
*   **Risks:** Dehydration/electrolyte imbalance from bowel prep, sedation risks, and physical risks like perforation or bleeding <a class="yt-timestamp" data-t="02:23:02">[02:23:02]</a>. However, a large study in the New England Journal of Medicine showed it to be a very safe procedure when performed by skilled professionals <a class="yt-timestamp" data-t="02:23:17">[02:23:17]</a>.
*   **Recommendations:** Standard recommendations are to start at age 45 (previously 50) <a class="yt-timestamp" data-t="02:24:12">[02:24:12]</a>. In clinical practice, for individuals with no family history or inflammatory bowel disease, screening might begin at age 40, and then every 3 years depending on findings <a class="yt-timestamp" data-t="02:24:27">[02:24:27]</a>.

### Prostate Cancer Screening
*   **PSA (Prostate-Specific Antigen) Test:** Used for screening. If PSA levels are high, further tests like a 4K test or multiparametric MRI may be warranted <a class="yt-timestamp" data-t="02:19:03">[02:19:03]</a>.

### Lung Cancer Screening
*   **Low-Dose CT (LDCT):** Justified for former or current smokers, as lung cancer is the leading cause of cancer death, and 85% of lung cancers occur in these groups <a class="yt-timestamp" data-t="02:32:38">[02:32:38]</a>. LDCT detects small cell, large cell, and squamous cell cancers best <a class="yt-timestamp" data-t="02:33:06">[02:33:06]</a>.
*   **MRI:** For never-smokers, adenocarcinoma of the lung (the dominant cause of lung cancer in non-smokers) can be detected equally well with an MRI, avoiding radiation risk <a class="yt-timestamp" data-t="02:33:14">[02:33:14]</a>.
*   **Radiation from CT Scans:** While CT scans carry more radiation than mammograms, advances have significantly reduced dosage. A CT angiogram that was 20 mSv 20 years ago (40% of annual radiation allotment) is now often less than 1 mSv <a class="yt-timestamp" data-t="02:34:51">[02:34:51]</a>. Exposure to more than 50 mSv a year is generally considered to increase mutagenesis risk <a class="yt-timestamp" data-t="02:34:13">[02:34:13]</a>.

## Liquid Biopsies (Galleri by Grail)

Liquid biopsies offer a different approach to cancer screening by analyzing cell-free DNA in the blood <a class="yt-timestamp" data-t="02:26:38">[02:26:38]</a>. The Grail test (Galleri) focuses on methylation patterns in DNA to indicate the presence of cancer and potentially its tissue of origin <a class="yt-timestamp" data-t="02:27:40">[02:27:40]</a>.

*   **Mechanism:** Grail looks at methylation patterns, which are specific to certain cancers and can reveal the tissue of origin <a class="yt-timestamp" data-t="02:27:52">[02:27:52]</a>.
*   **Sensitivity & Specificity:** The Grail test has a very high specificity (unlikely to give a false positive if no cancer is present) <a class="yt-timestamp" data-t="02:29:12">[02:29:12]</a>. Overall sensitivity for breast cancer (Stage 1 and 2) is about 20% <a class="yt-timestamp" data-t="02:29:43">[02:29:43]</a>, which seems low. However, for more aggressive, ER/PR negative breast cancers (Stage 1 and 2), the sensitivity is 75-80% <a class="yt-timestamp" data-t="02:30:17">[02:30:17]</a>. This suggests it may be better at detecting the more clinically significant cancers <a class="yt-timestamp" data-t="02:30:51">[02:30:51]</a>.
*   **Blood Cancers:** Liquid biopsies are particularly effective for blood cancers like leukemias and myelomas due to the higher concentration of cell-free DNA <a class="yt-timestamp" data-t="02:36:47">[02:36:47]</a>.
*   **Current Use:** Currently, liquid biopsies are not used in isolation but often in combination with morphological studies (imaging) <a class="yt-timestamp" data-t="02:31:17">[02:31:17]</a>. The hope is that in the future, liquid biopsies alone could be sufficient, with imaging only needed if the liquid biopsy is positive <a class="yt-timestamp" data-t="02:31:31">[02:31:31]</a>.

## Hormone Replacement Therapy (HRT) and Cancer Risk

The interpretation of the Women's Health Initiative (WHI) study in 2001-2002 led to a widespread misunderstanding that HRT increased breast cancer risk <a class="yt-timestamp" data-t="02:42:42">[02:42:42]</a>. This misinterpretation has led to millions of women being deprived of beneficial hormone therapy <a class="yt-timestamp" data-t="02:43:27">[02:43:27]</a>.

> [!important] Re-evaluating the WHI Study
> The WHI study involved older women (average 7-10 years post-menopause) given conjugated equine estrogen (CE) and a synthetic progestin (MPA) <a class="yt-timestamp" data-t="02:45:54">[02:45:54]</a>. The *relative* risk of breast cancer in the CE + MPA group was 25% higher (5 cases per 1,000 women vs. 4 cases in placebo), but the *absolute* risk was only 0.1% <a class="yt-timestamp" data-t="02:46:50">[02:46:50]</a>.
>
> Critically, there was *no difference in breast cancer mortality* in the CE + MPA group, even with 19-year follow-up data <a class="yt-timestamp" data-t="02:47:31">[02:47:31]</a>.
>
> Furthermore, in the CE-alone group (women without a uterus), there was a *lower* risk of breast cancer incidence and eventually lower mortality <a class="yt-timestamp" data-t="02:47:58">[02:47:58]</a>. This suggests that MPA, the synthetic progestin (which is rarely used today), was the likely driver of the statistically significant, but clinically insignificant, increase in breast cancer incidence <a class="yt-timestamp" data-t="02:48:29">[02:48:29]</a>.

Current evidence indicates that initiating HRT at menopause does not increase a woman's risk of heart disease, breast cancer, or other conditions; in fact, it reduces her risk of heart disease and bone mineral density (BMD) decline, and is either protective or neutral on cancer <a class="yt-timestamp" data-t="03:01:02">[03:01:02]</a>.

### Estrogen in HRT
*   **Bioidentical Estrogens:** Current HRT uses bioidentical estrogens, primarily estradiol (E2) <a class="yt-timestamp" data-t="02:50:47">[02:50:47]</a>.
*   **Delivery Methods:**
    *   **Oral Estradiol:** Generally avoided due to a small but non-zero increased risk of hypercoagulability <a class="yt-timestamp" data-t="02:52:46">[02:52:46]</a>.
    *   **Estradiol Patch (e.g., Vivelle-Dot):** Preferred method, providing a steady dose and allowing easy adjustments <a class="yt-timestamp" data-t="02:53:08">[02:53:08]</a>.
    *   **Topical Estrogen Creams:** Used for local vaginal symptoms if a woman does not want systemic estrogen <a class="yt-timestamp" data-t="02:54:50">[02:54:50]</a>.
    *   **Estrogen Pellets:** Inserted subq; not FDA-approved, but used by some physicians <a class="yt-timestamp" data-t="02:53:57">[02:53:57]</a>.

### Progesterone in HRT
*   For women with a uterus, progesterone is essential to prevent endometrial hyperplasia (thickening of the uterine lining) caused by unopposed estrogen, which can lead to endometrial cancer <a class="yt-timestamp" data-t="02:44:41">[02:44:41]</a>.
*   **Delivery Methods:** Bioidentical micronized oral progesterone or a progesterone-coated IUD <a class="yt-timestamp" data-t="02:49:02">[02:49:02]</a>.

### Testosterone in Women
*   Testosterone levels significantly decline in women post-menopause <a class="yt-timestamp" data-t="02:38:34">[02:38:34]</a>.
*   **Benefits:** Important for sexual function (libido, orgasmic function, arousal) <a class="yt-timestamp" data-t="03:14:00">[03:14:00]</a> and maintaining muscle mass, which is as imperative for women as for men <a class="yt-timestamp" data-t="03:14:59">[03:14:59]</a>.
*   **Dosage:** Physiological replacement doses are typically about one-tenth of what men take <a class="yt-timestamp" data-t="03:15:17">[03:15:17]</a>.

### Hormones and Alzheimer's Risk
*   Late initiation of HRT (e.g., 10 years post-menopause) may be counterproductive for Alzheimer's disease (AD) risk and could even increase it <a class="yt-timestamp" data-t="02:59:14">[02:59:14]</a>.
*   Early initiation appears potentially beneficial only in ApoE4 women, not ApoE3 women <a class="yt-timestamp" data-t="02:59:26">[02:59:26]</a>.

## Personalized Approach to Screening

A personalized approach considers individual risk appetite, family history, and other health factors. It also acknowledges the economic and emotional costs of screening <a class="yt-timestamp" data-t="02:18:21">[02:18:21]</a>.

The goal is to provide highly preventive, super early, personalized care by using advanced tests and interpreting them within the context of an individual's unique health profile <a class="yt-timestamp" data-t="03:42:17">[03:42:17]</a>. This often means going beyond standard of care guidelines to proactively manage disease risk.